Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 FLT201 gene therapy study in adults with Gaucher disease type 1
MOH_2026-02-23_015679Phase 3Not yet recruiting
- Sponsor
- Spur Therapeutics
- Start
- Feb 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of avigbagene parvec in Gaucher disease type 1 (GD1), sponsored by Spur Therapeutics. Primary endpoint: Stable hemoglobin concentration at week 52. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
avigbagene parvec
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on MOH_2026-02-23_015679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-23_015679.